Aspire Biopharma Stock Performance

ASBP Stock   0.06  0.02  26.44%   
The firm shows a Beta (market volatility) of -0.73, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Aspire BioPharma are expected to decrease at a much lower rate. During the bear market, Aspire BioPharma is likely to outperform the market. At this point, Aspire BioPharma has a negative expected return of -1.92%. Please make sure to confirm Aspire BioPharma's information ratio, potential upside, as well as the relationship between the Potential Upside and rate of daily change , to decide if Aspire BioPharma performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Aspire BioPharma has generated negative risk-adjusted returns adding no value to investors with long positions. Even with inconsistent performance in the last few months, the Stock's fundamental drivers remain relatively invariable which may send shares a bit higher in February 2026. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
1
Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall By Investing.com - Investing.com Nigeria
10/17/2025
2
Why LightPath Technologies Shares Are Trading Higher By 7 Here Are 20 Stocks Moving Premarket
11/12/2025
3
Why Gorilla Technology Shares Are Trading Higher By Around 14 Here Are 20 Stocks Moving Premarket - Benzinga
11/18/2025
4
Acquisition by Fell Donald G. of 10500 shares of Aspire BioPharma, at 0. subject to Rule 16b-3
11/28/2025
5
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Inf...
12/02/2025
6
Head-To-Head Analysis Aspire Biopharma and Its Peers
12/08/2025
7
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB Caffeine
12/18/2025
8
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin
01/07/2026
9
Aspire Biopharma Announces Reverse Stock Split
01/14/2026
Begin Period Cash Flow11.2 K
Total Cashflows From Investing Activities13.8 M

Aspire BioPharma Relative Risk vs. Return Landscape

If you would invest  32.00  in Aspire BioPharma on October 16, 2025 and sell it today you would lose (26.13) from holding Aspire BioPharma or give up 81.66% of portfolio value over 90 days. Aspire BioPharma is currently does not generate positive expected returns and assumes 12.0411% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Aspire, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Aspire BioPharma is expected to under-perform the market. In addition to that, the company is 17.08 times more volatile than its market benchmark. It trades about -0.16 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.16 per unit of volatility.

Aspire BioPharma Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Aspire BioPharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aspire BioPharma, and traders can use it to determine the average amount a Aspire BioPharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.1595

High ReturnsBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative ReturnsASBP
Based on monthly moving average Aspire BioPharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aspire BioPharma by adding Aspire BioPharma to a well-diversified portfolio.

Aspire BioPharma Fundamentals Growth

Aspire Stock prices reflect investors' perceptions of the future prospects and financial health of Aspire BioPharma, and Aspire BioPharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aspire Stock performance.

About Aspire BioPharma Performance

Assessing Aspire BioPharma's fundamental ratios provides investors with valuable insights into Aspire BioPharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Aspire BioPharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Return On Tangible Assets(97.42)(92.55)
Return On Capital Employed(0.08)(0.07)
Return On Assets(97.42)(92.55)
Return On Equity 9.36  17.05 

Things to note about Aspire BioPharma performance evaluation

Checking the ongoing alerts about Aspire BioPharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aspire BioPharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Aspire BioPharma generated a negative expected return over the last 90 days
Aspire BioPharma has high historical volatility and very poor performance
Aspire BioPharma has some characteristics of a very speculative penny stock
Aspire BioPharma has high likelihood to experience some financial distress in the next 2 years
Aspire BioPharma was previously known as PWUP Old and was traded on NASDAQ Exchange under the symbol PWUP.
Net Loss for the year was (12.54 M) with profit before overhead, payroll, taxes, and interest of 884.
Aspire BioPharma generates negative cash flow from operations
Aspire BioPharma has a poor financial position based on the latest SEC disclosures
About 14.0% of the company shares are held by company insiders
Latest headline from newswire.com: Aspire Biopharma Announces Reverse Stock Split
Evaluating Aspire BioPharma's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Aspire BioPharma's stock performance include:
  • Analyzing Aspire BioPharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aspire BioPharma's stock is overvalued or undervalued compared to its peers.
  • Examining Aspire BioPharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Aspire BioPharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aspire BioPharma's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Aspire BioPharma's stock. These opinions can provide insight into Aspire BioPharma's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Aspire BioPharma's stock performance is not an exact science, and many factors can impact Aspire BioPharma's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Aspire Stock Analysis

When running Aspire BioPharma's price analysis, check to measure Aspire BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aspire BioPharma is operating at the current time. Most of Aspire BioPharma's value examination focuses on studying past and present price action to predict the probability of Aspire BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aspire BioPharma's price. Additionally, you may evaluate how the addition of Aspire BioPharma to your portfolios can decrease your overall portfolio volatility.